Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REVELATION BIOSCIENCES, INC.PAIC · Entity 8359 | Director · Chief Executive Officer · 10% owner | December 30, 2020 | December 31, 2020 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REVELATION BIOSCIENCES, INC.
Report date December 30, 2020 · Filed December 31, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 1,769,538 |
Reported balance
After 2020-12-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2020-12-30 · Other · Disposed 192,962 · Balance 1,769,538 F2: On December 30, 2020, the Sponsor forfeited at no cost 192,962 shares of common stock of the Issuer in connection with the expiration of the underwriters over-allotment option in connection with the Issuer's initial public offering. F1: The reporting person is a member of Petra Investment Holdings, LLC ("Sponsor"). He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in Petra Investment Holdings, LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is a member of Petra Investment Holdings, LLC ("Sponsor"). He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in Petra Investment Holdings, LLC.
F2: On December 30, 2020, the Sponsor forfeited at no cost 192,962 shares of common stock of the Issuer in connection with the expiration of the underwriters over-allotment option in connection with the Issuer's initial public offering.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 30, 2020 Filed Dec 31, 2020 11:35 UTC | REVELATION BIOSCIENCES, INC. PAIC · Entity 8359 | OtherCommon Stock | 192,962 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-20-045618 · ownership.xml · nonDerivative · entry 1 TYPALDOS ANDREAS · CIK 0001098013 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,769,538 F2 · kind: On December 30, 2020, the Sponsor forfeited at no cost 192,962 shares of common stock of the Issuer in connection with the expiration of the underwriters over-allotment option in connection with the Issuer's initial public offering. F2 · price: On December 30, 2020, the Sponsor forfeited at no cost 192,962 shares of common stock of the Issuer in connection with the expiration of the underwriters over-allotment option in connection with the Issuer's initial public offering. F1 · ownership.nature: The reporting person is a member of Petra Investment Holdings, LLC ("Sponsor"). He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in Petra Investment Holdings, LLC. Read SEC document |
| October 16, 2020 Filed Oct 21, 2020 17:09 UTC | REVELATION BIOSCIENCES, INC. PAIC · Entity 8359 | OtherRedeemable Warrant · Derivative | 83,446 | $1.00 | $83,446.00 |
DisclosureSEC source: 0001213900-20-032604 · ownership.xml · derivative · entry 1 TYPALDOS ANDREAS · CIK 0001098013 · Director · Chief Executive Officer · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,233,446 Underlying: Common Stock · 83,446 shares Expires not disclosed F2 · security: Includes securities underlying private warrants of the Issuer. The purchase of these warrants was made on a private placement basis and was consummated pursuant to the Sponsor's Subscription Agreement for Private Warrants, dated October 7, 2020, simultaneously with the underwriters partial exercise of their over-allotment option on October 16, 2020 in connection with the Issuer's initial public offering. F3 · derivative.exercise_price: Each whole warrant entitles the holder to purchase one share of common stock at a price of $11.50 per share, subject to adjustment in the event of certain capital-raising transactions. F4 · derivative.exercise_date: Each warrant will become exercisable on the later of 30 days after the completion of the Issuer's initial business combination or October 7, 2021. F5 · derivative.expiration_date: Each warrant will expire five years after the completion of the Issuer's initial business combination. F1 · ownership.nature: The reporting person is a member of Petra Investment Holdings, LLC ("Sponsor"). He disclaims any pecuniary interest in the securities except to the extent of his ownership interest in Petra Investment Holdings, LLC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.